COMMUNIQUÉS West-GlobeNewswire

Alignment Health Plan Recognized Among U.S. News & World Report’s 2027 Best Insurance Companies for Medicare Advantage
20/10/2026
Alignment earns “Best” rating in Arizona, California, Nevada, North Carolina and Texas for the second consecutive year, reflecting strong performance in care quality, prevention and satisfaction ORANGE, Calif., Oct. 20 [...]
Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026
20/10/2026
ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release [...]
Medicovestor Announces FDA Fast Track Designation for MC001, Its First-in-Class Chemoimmunotherapy ADC for Pancreatic Cancer
20/10/2026
Designation follows recent IND activation and builds on Orphan Drug Designation granted in 2025. NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Medicovestor, Inc. today announced that the US Food and Drug Administration ( [...]
The Consortium for Top-Down Proteomics is now The Proteoform Alliance, with the Expanded Mission to Unlock the Full Potential of Proteoform Biology
20/10/2026
Proteoforms are the primary effectors of biological function, and uniting the various technologies, applications, and institutions in one organization will greatly increase our knowledge and capabilities for proteoform- [...]
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
20/10/2026
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on [...]
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
20/10/2026
BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases [...]
Kane Biotech Signs Distribution Agreement with The Stevens Company
20/10/2026
Expands Kane Biotech’s commercial footprint and access to the revyve ® product line across Canada WINNIPEG, Manitoba, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane [...]
Mammogen Names National Cancer Screening Leader, Dr. Rebecca Kaltman, to Lead Pivotal genTRU-breast™ Study
20/10/2026
Executive Director of the Inova Saville Cancer Screening and Prevention Center will lead KATELYN-ERIN, Mammogen’s large prospective study evaluating its blood-based RNA assay to support breast cancer detection NEWPORT [...]
PolarityBio Highlights Highest Scoring Abstract Award and Presentation of Phase 3 COVER DFUS II Trial Results at SAWC Fall 2026
20/10/2026
“Autologous Cutaneous Multicellular Units in Non-Healing Wagner 1 Diabetic Foot Ulcers: Results of the Phase 3 COVER DFUS II Trial” honored with top award in Clinical Research category Pivotal Phase 3 trial met primary [...]
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
20/10/2026
85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026 European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable [...]
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
20/10/2026
Correlation between clinical efficacy and changes in inflammatory biomarkers, mucosal transcriptomic signatures, and histologic disease activity strengthens the previously shown clinical proof of concept for OD-001 [...]
Slate Medicines Strengthens Board of Directors with Appointment of Stephen K. Brannan, MD, and John D. Young
20/10/2026
RALEIGH, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and [...]
Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
20/10/2026
YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN) Visara is a [...]
Abiologics Appoints Per Jr. Greisen as Chief Artificial Intelligence Officer
20/10/2026
AI protein design pioneer joins to advance first and only platform for de novo generation of synthetic D-protein therapeutics with supranatural properties WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Abiologics, [...]
ABBYY Introduces PHOENIX Plus, Advanced AI Models Optimized for Intelligent Document Processing
20/10/2026
PHOENIX Plus expands automation to any document type while improving accuracy and straight-through processing rates AUSTIN, Texas, Oct. 20, 2026 (GLOBE NEWSWIRE) -- ABBYY introduces PHOENIX Plus , a native generative AI [...]
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
20/10/2026
MAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026. Additionally, the [...]
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
20/10/2026
– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient’s Skin Improved [...]
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study
20/10/2026
Expansion Stage to Compare Opamtistomig Plus Chemotherapy Head-to-Head With Tislelizumab Plus Chemotherapy in Previously Untreated Disease NANJING, China, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd [...]
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
20/10/2026
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0. [...]

Pages